<style face="normal" font="default" size="100%">814 Enhancing anti-tumor response in ICI-refractory non-small cell lung cancer through intravenous administration of oncolytic adenovirus armed with hTNFα and hIL-2 in combination with aPD-1 blockade</style>

Drupal-HighWire